Relationship Between Serum N/OFQ and Acute Myeloid Cell Leukemia

AML Clinical Trial

— RBSNAAMCL  

Official title:

Relationship Between Serum N/OFQ and Acute Myeloid Cell Leukemia

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06469047
• Other study ID #: Hanyi20240408
• Status: Not yet recruiting
• Start date: June 20, 2024
• Est. completion date: December 31, 2024

Study information

• Verified date: June 2024
• Source: Second Hospital of Shanxi Medical University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Patients diagnosed with acute myeloid leukemia in the Second Hospital of Shanxi Medical University were selected and divided into the newly diagnosed group, the relapsed group, the complete remission group as the experimental group, and the healthy physical examination subjects as the control group. The relationship between IL-1β, catecholamine and norkephalin in peripheral blood of the experimental group and the control group was observed. According to the literature, the experimental group was significantly higher than the control group. In the experimental group, the newly diagnosed group was higher than the relapse group, and the relapse group was higher than the complete remission group, and the correlation was positive, and the difference was statistically significant.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 80
• Est. completion date: December 31, 2024
• Est. primary completion date: November 30, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• In accordance with adult acute myeloid leukemia (non-acute promyelocytic leukemia)The diagnostic criteria for AML in the Chinese Diagnosis and Treatment Guidelines (2017 edition); ?Leukocyte count = 25×109/L;
• No treatment has been received in the past 6 months.
• None of the candidates are related and known this study, and sign the informed consent.

Exclusion Criteria:

• Patients who are allergic to the drugs used in this study;
• People with mental illness or cognitive impairment;
• Patients with infectious diseases; ?Patients with severe heart, liver, kidney and other organ function lesions; ? Combined with other malignant swelling. The tumor.

Related Conditions & MeSH terms

• AML
• Leukemia

Intervention

Diagnostic Test:
• Enzyme-linked immunosorbent assay
Serum N/OFQ , IL-1ß and NE levels were detected.

Locations

Country	Name	City	State
China	Second Hospital of Shanxi Medical University	Taiyuan	Shanxi

Sponsors (1)

Lead Sponsor	Collaborator
Second Hospital of Shanxi Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	N/OFQ	Serum N/OFQ levels	24 hours
Primary	IL-1ß	Serum IL-1ß levels	24 hours
Primary	NE	Serum NE levels	24 hours